Abstract

Waters Corporation will release its quarterly results on August 04, 2026 Pre-Market; this preview summarizes consensus forecasts for revenue, margins, net profit and adjusted EPS alongside key segment dynamics and the latest institutional commentary from the past six months.

Market Forecast

Consensus indicates Waters Corporation’s current quarter revenue is estimated at 1.62 billion US dollars, with EBIT forecast at 393.31 million US dollars, adjusted EPS at 3.01, and year-over-year growth rates of 116.73% for revenue, 79.53% for EBIT, and 2.12% for adjusted EPS. Forecast commentary points to margin normalization with no explicit gross margin or net margin guidance provided in the forecast feed; the company’s last reported gross margin serves as a reference point while analysts look for EBIT leverage.

Waters Corporation’s main business mix last quarter was weighted toward Chemistry at 543.00 million US dollars, Instruments at 376.00 million US dollars, and Services at 348.00 million US dollars. The largest growth potential near term is expected in Instruments, where cyclical recovery in capex-led placements could expand revenue from its last-quarter base of 376.00 million US dollars with improving year-on-year comparisons.

Last Quarter Review

In the previous quarter, Waters Corporation delivered revenue of 1.27 billion US dollars, a gross profit margin of 46.41%, a GAAP net loss attributable to shareholders of 72.00 million US dollars with a net profit margin of -5.68%, and adjusted EPS of 2.70, marking a 91.48% year-over-year rise in total revenue and a 20.00% year-over-year increase in adjusted EPS. Quarter-on-quarter net profit growth, measured on the GAAP basis, was -131.97%, reflecting a swing to loss due to non-operating or one-off items despite positive operating growth.

A notable financial highlight was EBIT of 300.00 million US dollars, up 77.63% year over year and ahead of the prior estimate. Main business highlights showed revenue composition led by Chemistry at 543.00 million US dollars, followed by Instruments at 376.00 million US dollars and Services at 348.00 million US dollars, underscoring a balanced revenue base across consumables, hardware, and service contracts.

Current Quarter Outlook

Main business: Core LC-MS and chromatography franchise

Waters Corporation’s core revenue engine remains its chromatography and mass spectrometry ecosystem across Chemistry (consumables), Instruments (LC/LC-MS systems), and Services (service contracts and software). With the prior quarter showing a 46.41% gross margin and solid EBIT expansion, consensus expects operating leverage to persist as shipment timing normalizes and installed-base utilization supports consumables pull-through. Given the 1.62 billion US dollars revenue estimate and 393.31 million US dollars EBIT forecast, the current setup implies a stronger contribution from Instruments and Services alongside steady Chemistry, as laboratories recalibrate budgets. Seasonal dynamics and backlogs are likely to inform shipment linearity through the quarter, but the scale of the revenue estimate points to a robust order conversion cycle. The critical swing factor for the main business remains execution on high-end LC-MS placements and attach rates in consumables, which together should help stabilize mix and protect price realization.

Most promising business: High-value instrument placements and associated services

The most pronounced upside potential is centered on Instruments and the attach of Services, where the last quarter’s base was 376.00 million US dollars for Instruments and 348.00 million US dollars for Services. As laboratories in pharma and applied markets refresh their analytical platforms, each instrument placement can expand the medium-term annuity from service contracts and software, providing steadier cash flows. The consensus EBIT growth forecast of 79.53% on 116.73% revenue growth suggests incremental margins that benefit from scale, mix, and cost discipline. If placement activity continues to recover, the combined contribution from Instruments plus Services should outpace Chemistry growth, lifting overall margin quality. The pacing of orders from enterprise accounts and timing of regulatory lab validations will be the near-term determinants of how much of the backlog converts inside the reported quarter.

Key stock-price driver this quarter: Margin cadence and cash conversion

With adjusted EPS forecast at 3.01 and EBIT at 393.31 million US dollars, investors will focus on how much of the top-line step-up translates into operating profit and free cash flow. The last quarter’s GAAP net margin of -5.68% reflects non-operational noise relative to the robust EBIT trend, so clarity on non-recurring charges, interest expense, and tax rate will be crucial to reconcile GAAP-to-non-GAAP deltas. A repeat of high incremental margins would validate the consensus case for ongoing operating leverage and support confidence in multi-quarter EPS durability. Conversely, any sign of pricing pressure in consumables or slower-than-expected service attach could weigh on gross margin and limit EPS conversion even if revenue meets estimates. Management commentary around order intake, regional backlog momentum, and lead times will be closely parsed to gauge the sustainability of the current revenue run-rate.

Analyst Opinions

Across the recent six-month window, institutional commentary skews bullish, emphasizing a recovery in instrument demand and resilient consumables pull-through that should support revenue and EBIT outperformance versus the prior-year trough. Analysts arguing the bullish case highlight the 1.62 billion US dollars revenue estimate and the 79.53% forecast growth in EBIT as signals that Waters Corporation is entering a margin-acceleration phase as utilization improves and service revenue mix rises. The majority view expects adjusted EPS of roughly 3.01, with upside risk if instrument placements accelerate and operating expenses remain disciplined.

Prominent bullish takes point to the prior quarter’s stronger-than-expected EBIT of 300.00 million US dollars and adjusted EPS of 2.70 as evidence that execution has turned, despite GAAP noise. The constructive stance contends that higher-value LC-MS placements create a halo for consumables and services, increasing lifetime value per customer. While a minority of cautious voices remain focused on macro volatility and capex sensitivity in research labs, the prevailing opinion anticipates that near-term demand normalization will outweigh these factors. The bullish camp concludes that strong order conversion and improving mix can underpin revenue of 1.62 billion US dollars and EBIT of 393.31 million US dollars, setting a favorable base into the back half of the year.